Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30998
Title: | Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. | Austin Authors: | Eratne, Dhamidhu;Janelidze, Shorena;Malpas, Charles B;Loi, Samantha;Walterfang, Mark;Merritt, Antonia;Diouf, Ibrahima;Blennow, Kaj;Zetterberg, Henrik;Cilia, Brandon;Wannan, Cassandra;Bousman, Chad;Everall, Ian;Zalesky, Andrew;Jayaram, Mahesh;Thomas, Naveen;Berkovic, Samuel F ;Hansson, Oskar;Velakoulis, Dennis;Pantelis, Christos;Santillo, Alexander | Affiliation: | Medicine (University of Melbourne) Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Melbourne, VIC, Australia Clinical Outcomes Research Unit (CORe), Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, VIC, Australia The University of Melbourne, Parkville, VIC, Australia Mid West Area Mental Health Service, Melbourne Health, Sunshine, VIC, Australia Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden.. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden.. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.. Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.. UK Dementia Research Institute, University College London (UCL), London, UK.. Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.. Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.. Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.. Clinical Memory Research Unit, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.. Epilepsy Research Centre |
Issue Date: | Oct-2022 | Date: | 2021 | Publication information: | The Australian and New Zealand journal of psychiatry 2022; 56(10): 1295-1305 | Abstract: | Schizophrenia, a complex psychiatric disorder, is often associated with cognitive, neurological and neuroimaging abnormalities. The processes underlying these abnormalities, and whether a subset of people with schizophrenia have a neuroprogressive or neurodegenerative component to schizophrenia, remain largely unknown. Examining fluid biomarkers of diverse types of neuronal damage could increase our understanding of these processes, as well as potentially provide clinically useful biomarkers, for example with assisting with differentiation from progressive neurodegenerative disorders such as Alzheimer and frontotemporal dementias. This study measured plasma neurofilament light chain protein (NfL) using ultrasensitive Simoa technology, to investigate the degree of neuronal injury in a well-characterised cohort of people with treatment-resistant schizophrenia on clozapine (n = 82), compared to first-degree relatives (an at-risk group, n = 37), people with schizophrenia not treated with clozapine (n = 13), and age- and sex-matched controls (n = 59). We found no differences in NfL levels between treatment-resistant schizophrenia (mean NfL, M = 6.3 pg/mL, 95% confidence interval: [5.5, 7.2]), first-degree relatives (siblings, M = 6.7 pg/mL, 95% confidence interval: [5.2, 8.2]; parents, M after adjusting for age = 6.7 pg/mL, 95% confidence interval: [4.7, 8.8]), controls (M = 5.8 pg/mL, 95% confidence interval: [5.3, 6.3]) and not treated with clozapine (M = 4.9 pg/mL, 95% confidence interval: [4.0, 5.8]). Exploratory, hypothesis-generating analyses found weak correlations in treatment-resistant schizophrenia, between NfL and clozapine levels (Spearman's r = 0.258, 95% confidence interval: [0.034, 0.457]), dyslipidaemia (r = 0.280, 95% confidence interval: [0.064, 0.470]) and a negative correlation with weight (r = -0.305, 95% confidence interval: [-0.504, -0.076]). Treatment-resistant schizophrenia does not appear to be associated with neuronal, particularly axonal degeneration. Further studies are warranted to investigate the utility of NfL to differentiate treatment-resistant schizophrenia from neurodegenerative disorders such as behavioural variant frontotemporal dementia, and to explore NfL in other stages of schizophrenia such as the prodome and first episode. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30998 | DOI: | 10.1177/00048674211058684 | ORCID: | 0000-0002-3226-7645 0000-0003-1317-4635 0000-0002-5352-1075 0000-0001-6876-1015 0000-0002-9565-0238 |
Journal: | The Australian and New Zealand journal of psychiatry | PubMed URL: | 35179048 | Type: | Journal Article | Subjects: | Schizophrenia biomarker diagnosis neurofilament treatment-resistant |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.